3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
317
Rectal Neoplasms
235
Stomach Neoplasms
209
Pancreatic Neoplasms
137
Colonic Neoplasms
94
Neoplasm Metastasis
60
Esophageal Neoplasms
57
Neoplasms
40
Biliary Tract Neoplasms
39
Cholangiocarcinoma
31
Carcinoma, Hepatocellular
30
Gallbladder Neoplasms
29
Breast Neoplasms
28
Adenocarcinoma
22
Bile Duct Neoplasms
21
Locally Advanced Rectal Cancer
20
Adenocarcinoma Of Esophagus
20
Gastrointestinal Neoplasms
18
Liver Neoplasms
17
Esophageal Squamous Cell Carcinoma
17
Colorectal Cancer Metastatic
15
Carcinoma, Non-Small-Cell Lung
12
Anus Neoplasms
12
Parkinson Disease 4, Autosomal Dominant Lewy Body
11
Digestive System Neoplasms
7
Carcinoma
7
Advanced Gastric Cancer
7
Squamous Cell Carcinoma of Head and Neck
6
Ovarian Neoplasms
6
Klatskin Tumor
6
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Capecitabine
×
Gastrointestinal
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled